Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in oncology. | Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in oncology.

Tempus AI’s planned acquisition follows recent interest in blood-based cancer tests across the medtech industry.

Tempus is boosting its cancer offerings with a deal to buy out Personalis three years after the pair first teamed up in oncology. | Tempus is boosting its cancer offerings with a…